Breast Cancer
An orally bioavailable ER downregulator identified for breast cancer treatment
Published in Women's Health Weekly, October 13th, 2005
"Tamoxifen has been widely used for the treatment of estrogen receptor (ER)-positive breast cancer, but its partial agonist activity is considered to limit the efficacy, and cause tumor flare and endometrial cancer. Fulvestrant, on the other hand, binds and degrades ER, thereby acting as a pure antiestrogen without partial agonist activity," scientists in Japan report.
"However," contended T. Yoneya and colleagues, Chugai Pharmaceutical Co., "due to its low oral bioavailability, fulvestrant has to be intramuscularly administered to patients,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Back Pain
Teriparatide tested against alendronate for back pain in women with osteoporosis - Breast Cancer
Osteonectin expression inhibited MDA-MB-231 breast cancer cell metastasis - Cancer Risk Factors
EMSY gene evaluated for association in breast and ovarian cancer risk - Hormones
Role of circulating androgens in mid-life women examined - Medical Devices
Trocar-associated injuries and fatalities examined - Adverse Drug Reaction
Australian Agency urges caution over Paroxetine during pregnancy - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
